Valuation: EyePoint, Inc.

Market Cap 1.23B 1.08B 998M 922M 1.75B 118B 1.78B 11.91B 4.67B 57.65B 4.63B 4.53B 200B P/E 2026 *
-4.15x
P/E 2027 * -5.2x
Enterprise Value 940M 824M 760M 702M 1.33B 89.63B 1.35B 9.07B 3.56B 43.9B 3.53B 3.45B 152B EV / Sales 2026 *
531x
EV / Sales 2027 * 22.6x
Free-Float
96.33%
Yield 2026 *
-
Yield 2027 * -
1 day-0.81%
1 week+5.29%
Current month+2.94%
1 month+17.76%
3 months+3.74%
6 months-9.30%
Current year-19.43%
1 week 13.4
Extreme 13.4
14.99
1 month 11.93
Extreme 11.93
15.92
Current year 11.3
Extreme 11.295
18.87
1 year 9.4
Extreme 9.4
19.11
3 years 3.91
Extreme 3.91
30.99
5 years 2.19
Extreme 2.19
30.99
10 years 2.19
Extreme 2.19
42.5
Manager TitleAgeSince
Chief Executive Officer 67 09/07/2023
Director of Finance/CFO 61 13/11/2019
Chief Tech/Sci/R&D Officer 43 03/03/2024
Director TitleAgeSince
Director/Board Member 67 09/07/2023
Chairman 77 09/09/2018
Director/Board Member 73 24/10/2018
Date Insider Type Main position Quantity % Market Cap.
06-29Fiscal year

Chief Technology Officer

14,625 0.0174%
05-24Fiscal year

Chief Financial Officer

18,627 0.0222%
04-16Fiscal year

Chief Technology Officer

7,311 0.0088%
Change 5-day change 1-year change 3-year change Capi.($)
-0.81%+5.29%+42.08%+60.00% 1.23B
-2.33%-2.09%+49.88%+170.51% 1,060B
-0.82%-2.30%+63.79%+62.00% 619B
-0.73%-4.98%+28.91%+82.99% 438B
+0.33%-1.17%+31.07%+27.09% 333B
-0.02%-2.85%+29.15%+45.24% 282B
-3.89%-11.22%+22.81%+27.30% 267B
+0.66%-1.42%-26.59%-37.71% 218B
-0.06%-2.88%+23.07%+62.33% 196B
-3.72%-1.10%+18.41%+70.56% 161B
Average -1.14%-2.31%+28.26%+57.03% 357.51B
Weighted average by Cap. -1.31%-2.95%+36.75%+83.90%

Financials

2026 *2027 *
Net sales 1.77M 1.55M 1.43M 1.32M 2.51M 169M 2.55M 17.09M 6.7M 82.74M 6.65M 6.5M 287M 43.69M 38.3M 35.33M 32.64M 61.86M 4.17B 62.91M 422M 165M 2.04B 164M 160M 7.07B
Net income -315M -276M -255M -235M -446M -30.05B -454M -3.04B -1.19B -14.72B -1.18B -1.16B -50.98B -276M -242M -223M -206M -391M -26.33B -398M -2.66B -1.04B -12.89B -1.04B -1.01B -44.66B
Net Debt -294M -258M -238M -220M -417M -28.07B -424M -2.84B -1.11B -13.75B -1.1B -1.08B -47.61B -248M -218M -201M -185M -352M -23.68B -357M -2.4B -940M -11.6B -932M -912M -40.16B
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
214
Date Price Change Volume
10/07/26 US$14.72 -0.81% 1,638,977
09/07/26 US$14.84 +5.92% 1,570,866
08/07/26 US$14.01 -0.07% 1,899,461
07/07/26 US$14.02 -2.91% 2,117,886
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
14.72USD
Average target price
40.54USD
Spread / Average Target
+175.40%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EYPT Stock